P
Paul D. Smith
Researcher at AstraZeneca
Publications - 218
Citations - 12256
Paul D. Smith is an academic researcher from AstraZeneca. The author has contributed to research in topics: Selumetinib & Cancer. The author has an hindex of 53, co-authored 207 publications receiving 10843 citations. Previous affiliations of Paul D. Smith include National Institutes of Health & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.
Kostas Paschos,Paul D. Smith,Emma Anderton,Jaap M. Middeldorp,Robert E. White,Martin J. Allday +5 more
TL;DR: It is concluded that latent EBV initiates a chain of events that leads to epigenetic repression of the tumour suppressor gene Bim in infected B cells and their progeny and this reprogramming of B cells could have important implications for the understanding of EBV persistence and the pathogenesis ofEBV-associated disease, in particular BL.
Journal ArticleDOI
Challenges and Opportunities in Cancer Drug Resistance.
Richard A. Ward,Stephen Fawell,Nicolas Floc'h,Vikki Flemington,Darren Mckerrecher,Paul D. Smith +5 more
TL;DR: Common themes and approaches have been identified which have been utilized to successfully target emerging mechanisms of resistance and include the increase in target potency and selectivity, alternative chemical scaffolds, change of mechanism of action (covalents, PROTACs), increases in blood-brain barrier permeability (BBBP), and the targeting of allosteric pockets.
Journal ArticleDOI
Real time in vivo non-invasive optical imaging using near-infrared fluorescent quantum dots.
Nicole Y. Morgan,Sean J. English,Wei Chen,Victor Chernomordik,Angelo Russo,Paul D. Smith,Amir H. Gandjbakhche +6 more
TL;DR: In this paper, the use of NIR semiconductor nanocrystals in deep-tissue in vivo optical imaging is reported, which is a useful angiographic contrast agent for vessels surrounding and penetrating a murine squamous cell carcinoma in a C3H mouse.
Journal ArticleDOI
Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma
Y.N. Vashisht Gopal,Helen Rizos,Guo Chen,Wanleng Deng,Dennie T. Frederick,Zachary A. Cooper,Richard A. Scolyer,Gulietta M. Pupo,Kakajan Komurov,Vasudha Sehgal,Jiexin Zhang,Lalit R. Patel,Cristiano Gonçalves Pereira,Bradley M. Broom,Gordon B. Mills,Prahlad T. Ram,Paul D. Smith,Jennifer A. Wargo,Georgina V. Long,Michael A. Davies +19 more
TL;DR: The findings highlight the significance of OxPhos in melanoma and suggest that combined targeting of the MAPK and mTORC pathways may offer an effective therapeutic strategy to treat melanomas with this metabolic phenotype.
Journal ArticleDOI
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP
Fiamma Mantovani,Francesca Tocco,Javier E. Girardini,Paul D. Smith,Milena Gasco,Xin Lu,Tim Crook,Giannino Del Sal +7 more
TL;DR: It is found that Pin1 is required for efficient loading of p53 on target promoters upon stress and is recruited to chromatin by p53 and stimulates binding of the p300 acetyltransferase and consequent p53 acetylation.